![shutterstock_607718810_vchal](https://cdn.lifesciencesipreview.com/convert/files/2023/08/72525840-4112-11ee-8179-0f0ce8051b03-shutterstock_607718810_vchal.jpg/r%5Bwidth%5D=320/72525840-4112-11ee-8179-0f0ce8051b03-shutterstock_607718810_vchal.webp)
vchal / Shutterstock.com
21 August 2020BiotechnologyMuireann Bolger
LSPN Connect: CRISPR technologies
A lot of strides have been made in the field of CRISPR systems, and MilliporeSigma and Arbor Biotechnologies are at the heart of developments.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
10 September 2020 Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Generics
13 April 2021 Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Editor's picks
Editor's picks
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
10 September 2020 Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Generics
13 April 2021 Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.
Americas
31 July 2020 The development of CRISPR technology is showing no signs of losing momentum, and Arbor Biotechnologies is one company that is taking full advantage of this. We spoke to Kelly Morgan, senior director, head of IP and legal at the company to find out more.
Americas
10 September 2020 Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Generics
13 April 2021 Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.